8-K: Alkermes Reports Strong Second Quarter 2024 Results, Driven by Proprietary Product Growth

Alkermes announced a profitable second quarter of 2024, with a 16% year-over-year increase in net sales of proprietary products and GAAP net income from continuing operations of $94.7 million.

Summary

• Alkermes reported its financial results for the second quarter of 2024, showing a solid performance across its business.
• Total revenues for the quarter were $399.1 million, compared to $617.4 million in the same period last year, which included a one-time $245.5 million back royalty payment.
• Net sales of proprietary products increased by approximately 16% year-over-year, reaching $269.3 million.
• GAAP net income from continuing operations was $94.7 million, or $0.55 per diluted share.
• The company reiterated its financial expectations for 2024, including total revenues between $1.5 billion and $1.6 billion.
• LYBALVI revenues grew 52% year-over-year to $71.4 million, with total prescriptions increasing by 44%.
• ARISTADA revenues were $86.0 million, and new to brand prescriptions grew 6% sequentially compared to the first quarter of 2024.
• VIVITROL revenues reached $111.9 million, a 10% increase compared to the second quarter of 2023, driven by the alcohol dependence indication.
• The company repurchased approximately 3.5 million ordinary shares for $84.7 million during the quarter.
• Alkermes completed the sale of its Athlone, Ireland facility for approximately $91 million in cash.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong growth in proprietary product sales, particularly LYBALVI, and the reiteration of 2024 financial expectations. The company's profitability and strategic moves, such as the sale of the Athlone facility, further contribute to the positive outlook. However, the decrease in total revenue compared to the prior year due to the absence of a one-time payment tempers the sentiment slightly.

Positives

• The company achieved double-digit year-over-year growth in its proprietary commercial product portfolio.
• Alkermes reported robust profitability for the second quarter of 2024.
• LYBALVI showed strong growth with a 52% increase in revenue and a 44% increase in prescriptions year-over-year.
• VIVITROL experienced a 10% revenue increase, driven by the alcohol dependence indication.
• The company has a strong cash position with $962.5 million in cash, cash equivalents, and total investments.
• Alkermes is advancing its neuroscience development pipeline, including the phase 2 program for ALKS 2680 in narcolepsy.
• The company successfully completed the sale of its Athlone manufacturing facility for $91 million.

Negatives

• Total revenues decreased compared to the second quarter of 2023, primarily due to the absence of a large one-time royalty payment.
• GAAP net income from continuing operations decreased compared to the second quarter of 2023, due to the large one-time royalty payment in the prior year.
• EBITDA from continuing operations decreased compared to the second quarter of 2023, due to the large one-time royalty payment in the prior year.

Risks

• The company's future performance is subject to risks including unfavorable outcomes in litigation, potential adverse decisions by regulatory authorities, and challenges in commercializing products.
• There is a risk of reduced payment rates or reimbursement for the company's products.
• The company's products may face manufacturing difficulties, be precluded from commercialization by third-party rights, or have unintended side effects.
• The company's forward-looking statements are subject to a high degree of uncertainty and risk, and actual results may differ materially.

Future Outlook

Alkermes reiterated its 2024 financial expectations, projecting total revenues between $1.5 billion and $1.6 billion, and expects continued growth in its proprietary product sales.

Management Comments

• Richard Pops, Chief Executive Officer of Alkermes, stated that the second quarter results reflect solid execution across the business, delivering double-digit, year-over-year growth for the proprietary commercial product portfolio and robust profitability.
• He also mentioned that the company enters the second half of the year in a strong financial position with clear operational priorities to drive the performance of the commercial portfolio and advance the neuroscience development pipeline.

Industry Context

Alkermes operates in the competitive biopharmaceutical industry, focusing on neuroscience. The company's performance is being driven by its proprietary products, particularly LYBALVI, ARISTADA, and VIVITROL, which are used to treat conditions such as schizophrenia, bipolar disorder, alcohol dependence and opioid dependence. The company is also investing in its pipeline, including ALKS 2680 for narcolepsy, which is a key area of focus for the company.

Comparison to Industry Standards

• Alkermes' 16% year-over-year growth in proprietary product sales is a strong performance compared to many other mid-cap biopharmaceutical companies.
• The company's focus on neuroscience is aligned with a growing trend in the industry, with many companies investing in treatments for neurological disorders.
• LYBALVI's 52% revenue growth and 44% prescription growth are particularly impressive, indicating strong market adoption.
• The company's profitability, with a GAAP net income of $94.7 million, is a positive sign, especially in the biotech sector where many companies are not yet profitable.
• Compared to companies like Teva Pharmaceuticals and Lundbeck, which also have a focus on CNS drugs, Alkermes is showing strong growth in its key products.
• The sale of the Athlone facility for $91 million is a strategic move to streamline operations and focus on core business activities, similar to moves made by other companies in the sector to optimize their asset base.

Stakeholder Impact

• Shareholders will likely view the results positively due to the strong growth in proprietary product sales and the reiteration of 2024 financial expectations.
• Employees may be encouraged by the company's strong performance and continued investment in its pipeline.
• Customers will benefit from the continued availability of Alkermes' products.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's strong financial position favorably.

Next Steps

• The company will continue to focus on driving the performance of its commercial portfolio.
• Alkermes will advance its neuroscience development pipeline, including the phase 2 program for ALKS 2680 in narcolepsy.
• The company will continue to monitor and manage its financial performance in line with its 2024 expectations.

Key Dates

Keywords

Alkermes, Financial Results, Proprietary Products, LYBALVI, ARISTADA, VIVITROL, Neuroscience, Biopharmaceutical, Revenue, Net Income, EBITDA, Share Repurchase, ALKS 2680, Narcolepsy